Enter at least 3 characters
HOME > Press

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Accept this law
Chiesi renforce son engagement dans la lutte contre les maladies rares
Chiesi renforce son engagement dans la lutte contre les maladies rares
Chiesi Group continues to grow
Chiesi Group calls for #ActionOverWords in the fight against climate change
Chiesi organizes the 1st roundtable dedicated to the mission-oriented companies in the field of health & well-being
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Farmaceutici President appointed Knight of the Légion d’Honneur
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi France, fait évoluer son Comité de Direction avec 3 nouvelles nominations
Chiesi, accompagné par IBM, lance WeStart, son premier programme d’innovation ouverte fondé sur le partage et la collaboration.
Chiesi outlines €350 million investment and announces the development of the first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD
Le groupe Chiesi reçoit le prix Diversity Leaders Award 2020
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
COPD, a disease still underestimated by Europeans
The Chiesi Group is one of the 8 Italian companies invited by Macron to the French International Summit in Versailles
Chiesi France executive committee evolution
Chiesi France moving Forward
Appointment of Patrice Carayon